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Abstract
Background Liver disease progression after Hepatitis C Virus (HCV) eradication following direct-acting antiviral (DAA) 
treatment in the real-life setting according to Human Immunodeficiency Virus (HIV) coinfection was evaluated.
Methods Patients consecutively enrolled in PITER between April 2014 and June 2019 and with at least 12-weeks follow-up 
following treatment were analysed. Cox regression analysis were used to evaluate HIV coinfection and factors independently 
associated with liver disease outcomes following viral eradication in DAA treated patients with pre-treatment liver cirrhosis.
Results 93 HIV/HCV coinfected and 1109 HCV monoinfected patients were evaluated during a median follow-up of 26.7 
(range 6–44.6) and 24.6 (range 6.8–47.3) months, respectively. No difference in the cumulative HCC incidence and hepatic 
decompensation was observed between coinfected and monoinfected patients. Age (Hazard Ratio [HR] = 1.08; 95% CI 
1.04–1.13), male sex (HR = 2.76; 95% CI 1.28–5.96), lower albumin levels (HR = 3.94; 95% CI 1.81–8.58), genotype 3 
(HR = 5.05; 95% CI 1.75–14.57) and serum anti-HBc positivity (HR = 1.99, 95% CI 1.01–3.95) were independently associ-
ated with HCC incidence. Older age (HR = 1.03; 95% CI 1.00–1.07), male sex (HR = 2.13; 95% CI 1.06–4.26) and lower 
albumin levels (HR = 3.75; 95% CI 1.89–7.46) were independently associated with the appearance of a decompensating 
event after viral eradication.
Conclusion Different demographic, clinical and genotype distribution between HIV coinfected vs those monoinfected, was 
observed in a representative cohort of HCV infected patients in Italy. Once liver cirrhosis is established the disease progres-
sion is decreased, but still persists regardless of viral eradication in both coinfected and monoinfected patients. In patients 
with cirrhosis, HIV coinfection was not associated with a higher probability of liver complications, after viral eradication.
Keywords Hepatitis C virus · Human immunodeficiency virus · Coinfection · Real-life cohort · Direct-acting antivirals · 
Advanced liver disease · Sustained virological response · Clinical outcomes · Cirrhosis · Hepatocellular carcinoma · Viral 
eradication
Introduction
Worldwide, approximately 2.3 million people are co-infected 
with Human Immunodeficiency Virus (HIV) and Hepatitis 
C Virus (HCV), giving rise to a global co-infection preva-
lence in HIV infected individuals of 6.2% [1]. It is known 
that HIV accelerates the course of HCV-related chronic liver 
disease. Patients have a faster progression of liver fibrosis, 
a higher risk of developing cirrhosis, liver decompensation, 
hepatocellular carcinoma (HCC), and liver-related mortality 
and this effect is not completely reverted by antiretroviral 
therapy [2–4].
The development of direct-acting antivirals (DAAs) 
has revolutionized the treatment of HCV, with very high 
cure rates [5, 6]. The achievement of sustained virological 
response 12 weeks after completion of treatment (SVR12) 
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has been associated with improved liver function, decreased 
clinical complications and all-cause mortality [7–10]. With 
regard to HIV coinfection, inferior treatment response in 
patients with HIV is no longer a concern and regimens 
proven efficacious in HCV monoinfection are widely appli-
cable to patients with HIV [11]. However, little is known 
about whether HIV coinfection modifies outcomes of HCV-
related liver disease after achieving SVR.
The aim of the present analysis was to evaluate the soci-
odemographic and clinical profile of HIV/HCV coinfected 
vs HCV monoinfected patients in a real-life patients’ cohort 
with the final goal to prospectively evaluate the clinical 
impact of DAA treatment in patients with progressive/severe 
liver disease according to HIV coinfection status.
Methods
Study design and patients
The study population consisted of patients with chronic 
HCV infection consecutively enrolled in Piattaforma Itali-
ana per lo studio della Terapia delle epatiti ViRali (PITER) 
between April 2014 and June 2019, who were not receiving 
HCV treatment at the time of inclusion, and could be consid-
ered representative of the HCV chronic infected population 
in care in Italy [12].
For the present study, we included all consecutively 
enrolled HCV-infected patients (any stage, any genotype, 
including HIV/HCV coinfected patients and HCV monoin-
fected patients with known HIV negative status).
For each patient, baseline demographic, clinical and labo-
ratory characteristics were recorded during the patient’s visit 
at treatment start. Further data were recorded during the 
follow-up after completion of treatment.
Fibrosis stage was defined based on liver transient elas-
tography data, which were considered as validated if each 
patient had at least 10 valid stiffness measurements, with a 
success rate of at least 80%, an interquartile range of less 
than 30% of the median stiffness score, and a body mass 
index (BMI) of < 30 kg/m2 [13]. Liver cirrhosis was defined 
when the stiffness score was equal to or higher than 12.5 kPa 
or according to biochemical and instrumental data of portal 
hypertension [13].
Decompensated cirrhosis was diagnosed according to the 
presence or appearance of ascites and/or portal hyperten-
sive gastrointestinal bleeding and/or hepatic encephalopathy. 
Ascites was detected by ultrasound as routine evaluation in 
each outpatient or inpatient with cirrhosis.
Outcome variables
The study outcomes following HCV eradication were 
evaluated in DAA treated patients with pre-treatment diag-
nosis of liver cirrhosis. Patients with a history of decom-
pensated cirrhosis or liver transplantation prior to treat-
ment were excluded from this analysis considering their 
different pathogenesis compared to patients with chronic 
hepatitis and liver cirrhosis without complications. Clini-
cal outcomes evaluated following the SVR12 included the 
appearance of incident HCC and the first occurrence of a 
decompensating event.
Statistical analysis
Patient’s main baseline characteristics were reported as 
median and range or as proportions (N and %) for con-
tinuous and categorical variables, respectively. The 
Mann–Whitney U test was used for continuous variables 
to assess differences between distribution, and the Chi-
squared test was used for comparisons of proportions. A 
p value of < 0.05 was considered statistically significant. 
De novo HCC and decompensating event occurrences in 
HCV monoinfected and HIV/HCV coinfected groups were 
examined using Kaplan–Meier survival analyses. The log-
rank test was used to identify significant differences in 
survival between groups.
Variables independently associated to HCC incidence 
and the appearance of a decompensating event following 
viral eradication were evaluated by Cox proportional haz-
ard models adopting a forward stepwise selection, adding 
terms with p ≤ 0.1 and removing those with p ≥ 0.2.
To confirm the main results of the analyses, the propen-
sity score was estimated using a nonparsimonious logistic 
regression model with the HIV infection as the depend-
ent variable and all measured potential confounders as 
covariates. The following variables at baseline have been 
included: age, sex, BMI, alcohol, ALT, AST, platelets, 
albumin, bilirubin, INR, genotype, diabetes, anti-HBc, 
HBsAg, previous Interferon, HCC. Relationship between 
each outcome and HIV adjusted by propensity score was 
evaluated by multiple Cox regression analyses.
All analyses were performed using the STATA/SE 15.1 
statistical package (StataCorp LP, College Station, TX, 
USA).




Data from 244 HIV/HCV coinfected patients (74.6% 
males) and 2870 HCV monoinfected patients with known 
HIV negative status (54.1% males), treated with DAA and 
with a median follow-up since enrollment of 38.9 months 
(range 4.1–60.8), were included. The baseline demo-
graphic, clinical and biochemical characteristics are shown 
in Table 1.
The median age of the coinfected and monoinfected 
patients was 52 years (range 32–77) and 61 years (range 
20–86), respectively (p < 0.001).
Compared to monoinfected patients, coinfected patients 
had a significant lower BMI [66.4% of coinfected patients 
were in the normal BMI group, while monoinfected 
patients were equally distributed between the normal 
(47.1%) and the overweight group (defined as having a 
BMI of ≥ 25 and < 30 kg/m2) (40.4%); p < 0.001].
Genotype 1a and 3 were prevalent in coinfected patients 
(n = 80, 32.8% and n = 65, 26.6%, respectively), whereas 
about half of the monoinfected patients (n = 1438, 50.1%) 
were infected by HCV genotype 1b (p < 0.001).
Serum anti-HBc was detected in 98 (40.2%) coinfected 
and in 591 (20.6%) monoinfected patients (p < 0.001). No 
difference was found in HBsAg positivity between coin-
fected and monoinfected patients (2.1% vs 1.2%, p > 0.05).
There were no significant differences among coinfected 
and monoinfected patients for baseline alanine transami-
nase (ALT), aspartate transaminase (AST), platelet count, 
serum albumin, bilirubin and international normalized 
ratio (INR) value.
Overall, 101 (49.5%) coinfected patients and 1164 
(45.5%) monoinfected patients were classified in the F4/
cirrhosis stage. A decompensating event occurred prior to 
treatment in 20 (9.8%) and in 162 (6.3%) coinfected and 
monoinfected patients, respectively (p > 0.05). No differ-
ences in the prevalence of liver transplantation, among 
coinfected and monoinfected patients, were observed prior 
to antiviral treatment.
Clinical outcomes following SVR12 in patients 
with liver cirrhosis
The post-treatment liver disease outcomes, were evalu-
ated in DAA treated patients with pre-treatment diagnosis 
of liver cirrhosis who achieved SVR12. Patients with a 
history of decompensated cirrhosis or liver transplanta-
tion prior to treatment were excluded by this analysis as 
reported in the methods section.
Similar rates of SVR12 were observed in coinfected 
(94.9%) and monoinfected (94.8%) patients with liver cir-
rhosis. Coinfected and monoinfected patients were evaluated 
during a median follow-up of 26.7 (range 6–44.6) and 24.6 
(range 6.8–47.3) months after viral eradication, respectively. 
Baseline characteristics of these patients are summarized 
in Table 2.
Coinfected patients were observed to have a significantly 
younger age (median age of 52 vs 64 years, p < 0.001) and 
increased liver disease severity in terms of Child–Pugh 
(C–P) class distribution (C–P class A: 83.3% vs 96.6%; 
C–P class B: 16.7% vs 3.4%), compared to HCV mono-
infected patients (p < 0.001). Prior to antiviral treatment, 
no difference in the prevalence of HCC, among coinfected 
and monoinfected patients, was observed. Serum anti-HBc 
was detected in 42 (45.2%) coinfected and in 248 (22.4%) 
monoinfected patients (p < 0.001). No difference was found 
in HBsAg positivity between coinfected and monoinfected 
patients (3.2% vs 1.3%, p > 0.05).
Overall, no significant differences were observed among 
coinfected and monoinfected patients for the different 
outcomes evaluated. Following viral eradication, similar 
cumulative incidence of HCC was observed in coinfected 
(in 2 patients = 2.2%) and monoinfected patients (in 40 
patients = 3.9%) (p > 0.05). The occurrence of a decompen-
sating event was observed in 4 (4.3%) of coinfected patients 
and in 53 (4.8%) of monoinfected patients. No differences 
on the incidence of HCC and of decompensating event after 
viral eradication were observed between the two groups, as 
shown by Kaplan–Meier curves (log-rank test p = 0.390 and 
p = 0.837, respectively) (Figs. 1 and 2).
Predictors of clinical outcomes following SVR12
Following Cox regression analysis, it was observed that age 
(increasing years; HR = 1.08; 95% CI 1.04-1.13), male sex 
(HR = 2.76; 95% CI 1.28–5.96), lower baseline albumin lev-
els (HR = 3.94 95%; CI 1.81–8.58), genotype 3 (HR = 5.05; 
95% CI 1.75–14.57) and serum anti-HBc positivity 
(HR = 1.99; 95% CI 1.01–3.95) were factors independently 
associated with de novo HCC occurrence after successful 
DAA treatment (Table 3).
Factors independently associated with the appearance 
of a decompensating event included age (increasing years; 
HR = 1.03; 95% CI 1.00–1.07), male sex (HR = 2.13; 95% 
CI 1.06–4.26) and lower baseline albumin levels (HR = 3.75 
95%; CI 1.89–7.46) (Table 4).
As shown in Tables 3 and 4, HIV coinfection was not 
associated with a higher probability of developing liver 
complications (HCC or the appearance of a decompensat-
ing event). In addition, because observational studies do 
not provide randomization, the propensity score method 
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Table 1  Patients’ main baseline characteristics
p values < 0.05 are reported in bold
*For some variables inconsistencies are due to missing values
**p value Mann–Whitney rank-sum test.
***p value Chi-squared test
Quantitative variables All patients (N = 3114*) HIV/HCV coinfected (N = 244*) HCV monoinfected (N = 2870*) p**
Median (Range) Median (Range) Median (Range)
Age (years) 59 (20–86) 52 (32–77) 61 (20–86) < 0.001
ALT (IU/L) 61.0 (7.0–969.0) 56.0 (10.0–301.0) 61.0 (7.0–969.0) 0.1439
AST (IU/L) 54.0 (11.0–652.0) 53.0 (15.0–371.0) 55.0 (11.0–652.0) 0.5986
Platelets/µL 160000 (15,000–752,000) 153,500 (29,000–540,000) 160,000 (15,000–752,000) 0.0569
Albumin (g/dL) 4.0 (0.4–7.5) 4.0 (0.4–5.1) 4.0 (0.5–7.5) 0.8547
Bilirubin (mg/dL) 0.8 (0.1–70.0) 0.7 (0.1–58.0) 0.8 (0.1–70.0) 0.4100
INR 1.0 (0.5–9.0) 1.0 (0.7–1.5) 1.0 (0.5–9.0) 0.1863
Categorical variables N. (%) N. (%) N. (%) p***
Sex
 Male 1736 (55.8) 182 (74.6) 1554 (54.2) < 0.001
 Female 1378 (44.3) 62 (25.4) 1316 (45.9)
BMI
 Underweight 71 (2.3) 13 (5.3) 58 (2.0) < 0.001
 Normal 1513 (48.6) 162 (66.4) 1351 (47.1)
 Overweight 1216 (39.1) 58 (23.8) 1158 (40.4)
 Obese 313 (10.1) 11 (4.5) 302 (10.5)
Alcohol use
Never 1978 (65.2) 104 (47.1) 1874 (66.6) < 0.001
Current 441 (14.5) 73 (33.0) 368 (13.1)
Past 615 (20.3) 44 (19.9) 571 (20.3)
Genotype
 1 (Non subtyped) 108 (3.5) 17 (7.0) 91 (3.2) < 0.001
 1a 472 (15.2) 80 (32.8) 392 (13.7)
 1b 1467 (47.1) 29 (11.9) 1438 (50.1)
 2 478 (15.4) 11 (4.5) 467 (16.3)
 3 352 (11.3) 65 (26.6) 287 (10.0)
 4–5 237 (7.6) 42 (17.2) 195 (6.8)
Diabetes
 Yes 439 (14.1) 26 (10.7) 413 (14.4) 0.108
 No 2675 (85.9) 218 (89.3) 2457 (85.6)
Anti-HBc+
 Yes 689 (22.1) 98 (40.2) 591 (20.6) < 0.001
 No 2425 (77.9) 146 (59.8) 2279 (79.4)
HBsAg+
 Yes 39 (1.3) 5 (2.1) 34 (1.2) 0.244
 No 3075 (98.8) 239 (98.0) 2836 (98.8)
Previous interferon
 Yes 916 (29.4) 55 (22.5) 861 (30.0) 0.014
 No 2198 (70.6) 189 (77.5) 2009 (70.0)
Liver disease stage
 F0–F3 1246 (45.1) 81 (39.7) 1165 (45.6) 0.057
 F4-cirrhosis 1265 (45.8) 101 (49.5) 1164 (45.5)
 Decompensated  cirrhosis 182 (6.6) 20 (9.8) 162 (6.3)
 Liver transplantation 68 (2.5) 2 (1.0) 66 (2.6)
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Table 2  Baseline characteristics of cirrhotic patients successfully treated with DAA
p values < 0.05 are reported in bold
* For some variables inconsistencies are due to missing values
**p value Mann–Whitney rank-sum test
***p value Chi-squares test
Quantitative variables HIV/HCV coinfected (N = 93*–SVR 94.9%) HCV monoinfected (N = 1109*- SVR 94.8%) p**
Median (Range) Median (Range)
FU time since EOT (months) 26.7 (6.0–44.6) 24.6 (6.8–47.3) 0.7595
Age (years) 52 (36–77) 64 (23–86) < 0.001
ALT (IU/L) 65.5 (11.0–268.0) 76.5 (10.0–797.0) 0.0365
AST (IU/L) 63.5 (23.0–371.0) 71.0 (13.0–652.0) 0.3184
Platelets/µL 115,000 (29,000–262,000) 121,000 (15,000–510,000) 0.2817
Albumin (g/dL) 4.0 (3.0–5.1) 4.0 (2.1–7.3) 0.9712
Bilirubin (mg/dL) 0.8 (0.3–7.0) 0.9 (0.2–15.5) 0.6845
INR 1.1 (0.9–1.5) 1.1 (0.6–5.0) 0.6735
Categorical variables N. (%) N. (%) p***
Sex
 Male 74 (79.6) 642 (57.9) < 0.001
 Female 19 (20.4) 467 (42.1)
BMI
 Underweight 5 (5.4) 11 (1.0) < 0.001
 Normal 59 (63.4) 463 (41.8)
 Overweight 22 (23.7) 489 (44.1)
 Obese 7 (7.5) 145 (13.1)
Alcohol use < 0.001
Never 43 (51.2) 716 (65.9)
Current 25 (29.8) 109 (10.0)
Past 16 (19.1) 261 (24.0)
Genotype
1 (Non subtyped) 5 (5.4) 31 (2.8) < 0.001
 1a 29 (31.2) 157 (14.2)
 1b 13 (14.0) 592 (53.4)
 2 4 (4.3) 156 (14.1)
 3 25 (26.9) 104 (9.4)
 4–5 17 (18.3) 69 (6.2)
Diabetes
 Yes 11 (11.8) 220 (19.8) 0.060
 No 82 (88.2) 889 (80.2)
Anti-HBc+
 Yes 42 (45.2) 248 (22.4) < 0.001
 No 51 (54.8) 861 (77.6)
HBsAg+
 Yes 3 (3.2) 14 (1.3) 0.124
 No 90 (96.8) 1095 (98.7)
Previous interferon
 Yes 26 (28.0) 375 (33.8) 0.250
 No 67 (72.0) 734 (66.2)
HCC
 Yes 1 (1.1) 55 (5.0) 0.088
 No 92 (98.9) 1054 (95.0)
Child–pugh class
 A 50 (83.3) 940 (96.6) < 0.001
 B 10 (16.7) 33 (3.4)
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was applied taking into account the different background 
between coinfected and monoinfected groups, to ascertain 
the impact of HIV coinfection on liver disease outcomes. By 
Cox regression analyses, using HIV and propensity score 
as independent covariates, it was confirmed that neither de 
novo HCC appearance (HR = 0.72; 95% CI 0.09–6.10) nor 
hepatic decompensation (HR = 0.76; 95% CI 0.09–6.21) 
were influenced by HIV coinfection.
Discussion
Different countries have built specific registries regarding 
HCV and HIV infections. Most of collected data aims to 
evaluate the dimension of HCV chronic infection among 
HIV-infected patients and are mainly focused on the opti-
mization of cART [14–19]. The consecutive nature of the 
enrolled patients and the involvement of clinical centers 
of different specialties that deal with monoinfected and 
coinfected patients (i.e., gastroenterology/hepatology, 
internal medicine and infectious diseases) all over Italy, 
independently by the access to the therapy, are impor-
tant peculiarities of PITER cohort. The results in term 
of demographic, clinical and virological characteristics 
of the enrolled patients according to HCV coinfected and 
monoinfected patients are pretty similar with those of 
coinfected patients reported by ICONA cohort [15] and 
different regional cohorts of patients with chronic HCV 
in Italy (data available in www.proge ttopi ter.it). Moreo-
ver, the characteristics of treated patients in the PITER 
cohort are very similar with overall treated patients in Italy 
(data available in www.proge ttopi ter.it). For these reasons, 
PITER is reasonably considered representative of HCV 
and HIV/HCV coinfected patients in care in Italy.
Regarding HCV-infected patients enrolled in the PITER 
cohort, their median age is at least one to two decades 
older compared to other European cohorts of monoinfected 
patients which reflects the cohort effect of HCV infected 
individuals in Italy [20]. The mean age of HIV coinfected 
patients in care is about one decade younger than monoin-
fected patients, although older compared to other coinfected 
European cohorts. This data could be potentially explained 
by the higher prevalence of injection drug use vs sexual 
transmission as the main route of HIV transmission in Italy 
in the past. However, higher mortality rates in HIV coin-
fected patients, due to the lack of high efficacy of highly 
active antiretroviral therapy (HAART) in the past, could not 
be ruled out in explaining this different age pattern of coin-
fected compared to monoinfected patients in care in Italy.
Regarding HCV genotype distribution, genotype 1b is 
prevalent in monoinfected patients, associated with blood 
transfusion and unsafe medical procedures (more plausible 
route of infection in HCV monoinfected patients in Italy), 
whereas genotype 1a and 3 were dominant in coinfected 
patients, being mostly intravenous drug use-related (most 
risk factor in Italian HIV coinfected patients) [21, 22].
The presence of a high proportion of liver cirrhosis in 
coinfected and monoinfected patients enrolled and sub-
sequently treated for HCV infection, could reflect the 
N. events observed:
HCV monoinfected = 40 (3.9%)
HIV/HCV coinfected = 2 (2.2%)
Log-rank test 
p = 0.3890
Fig. 1  Kaplan–Meier curves for de novo HCC occurrence by HCV 
monoinfected and HIV/HCV coinfected groups
N. events observed:
HCV monoinfected = 53 (4.8%)
HIV/HCV coinfected = 4 (4.3%)
Log-rank test 
p = 0.8372
Fig. 2  Kaplan–Meier curves for decompensating event by HCV 
monoinfected and HIV/HCV coinfected groups
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prioritization criteria for the access to DAA treatment of 
patients with advanced liver cirrhosis during 2015–2016 
in Italy (www.aifa.gov.it).
Taking into account the younger overall mean age of the 
coinfected patients and at least one-decade younger age of 
those with severe liver disease compared to monoinfected 
Table 3  Variables associated 
with de novo HCC occurrence. 
Univariate and multivariate 
aanalysis
Statistically significant hazard ratios and related 95% confidence intervals are reported in bold
a Cox forward stepwise selection
b Not estimable due to insufficient cases
Baseline factors Crude HR (95% CI) Adjusted HR (95% CI)
HIV infection 0.54 (0.13–2.24) 0.60 (0.08 4.77)
Age (increasing years) 1.06 (1.03–1.10) 1.08 (1.04–1.13)
Sex (ref. female) 2.68 (1.28–5.60) 2.76 (1.28–5.96)
BMI: overweight/obese (ref. under-normal 
weight)
1.07 (0.58–1.98)
Current alcohol use (ref. never) 1.73 (0.70–4.32)
Past alcohol use (ref. never) 2.13 (1.09–4.16)
ALT (increasing IU/L) 1.00 (0.99–1.00)
AST (increasing IU/L) 1.00 (0.99–1.01)
Platelets (ref. > 100,000/µL) 1.50 (0.81–2.79)
Albumin (decreasing g/dL) 4.53 (2.24–9.13) 3.94 (1.81–8.58)
Bilirubin (increasing mg/dL) 1.15 (0.94–1.42)
INR (increasing unit) 1.17 (0.36–3.81)
Genotype (3 vs others) 1.68 (0.75–3.79) 5.05 (1.75–14.57)
Diabetes 0.95 (0.44–2.06)
Anti-HBc + 2.07 (1.12–3.84) 1.99 (1.01–3.95)
HBsAg+ Not  estimableb
Previous interferon 0.94 (0.50–1.79)




Statistically significant hazard ratios and related 95% confidence intervals are reported in bold
a Cox forward stepwise selection
Baseline factors Crude HR (95% CI) Adjusted HR (95% CI)
HIV infection 0.90 (0.32–2.49) 0.55 (0.07–4.32)
Age (increasing years) 1.03 (1.00–1.05) 1.03 (1.00–1.07)
Sex (ref. female) 1.58 (0.91–2.77) 2.13 (1.06–4.26)
BMI: overweight/obese (ref. under-normal 
weight)
0.93 (0.71–1.20)
Current alcohol use (ref. never) 1.36 (0.56–3.29)
Past alcohol use (ref. never) 2.17 (1.24–3.82) 1.84 (0.97–3.50)
ALT (increasing IU/L) 1.00 (0.99–1.00)
AST (increasing IU/L) 1.00 (0.99–1.01)
Platelets (ref. > 100,000/µL) 1.95 (1.16–3.29) 1.73 (0.93–3.20)
Albumin (decreasing g/dL) 4.66 (2.54–8.56) 3.75 (1.89–7.46)
Bilirubin (increasing mg/dL) 0.99 (0.69–1.42)
INR (increasing unit) 2.11 (1.27–3.50)
Genotype (3 vs others) 1.26 (0.57–2.79)
Diabetes 1.57 (0.88–2.81)
Anti-HBc + 0.47 (0.22–1.00)
HBsAg + 1.03 (0.14–7.48)
Previous Interferon 0.74 (0.41–1.32)
HCC 1.85 (0.67–5.13)
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patients, our data confirm that patients with HIV coinfec-
tion progress to advanced liver disease earlier in the natural 
history of chronic HCV infection compared to HCV mono-
infected patients [2, 3].
A similar benefit of DAA-based treatment regimens on 
liver disease severity in both coinfected and monoinfected 
patients with liver cirrhosis was observed. After successful 
DAA treatment, preliminary data have shown an improve-
ment in Child–Pugh class (observed in 85% of coinfected 
and in 65.9% of monoinfected patients, with no significant 
difference between the two groups), suggesting that viral 
eradication helps liver function recovery in the majority 
of patients with liver cirrhosis (data not shown). As pre-
viously reported, HCV cured after DAA therapy induce a 
reduction of the risk of HCC occurrence compared with 
non-responders; however, a residual risk still persists 
even after viral eradication [23–26]. In particular, regard-
ing the HCC occurrence following viral eradication, the 
cumulative incidence was 2.2% in coinfected and 3.9% in 
monoinfected patients, significantly lower compared to the 
cumulative incidence of HCC (13.8%) reported in patients 
who experienced treatment failure in the PITER cohort 
[23]. However, careful follow-up is important not only in 
patients with virological failure or with known risk factors 
(i.e., decompensation of liver cirrhosis prior to antiviral 
treatment or a “cured” HCC), but also in patients with F4 
fibrosis stage/liver cirrhosis prior to viral eradication. The 
cumulative incidence reported in this study is similar with 
previously reported incidence of newly diagnosed HCC at 
1 year after exposure to DAA [9, 24–26]. In patients with 
advanced hepatitis C receiving DAA, the residual HCC 
risk might be lower than that of untreated patients and 
declines progressively with time after a sustained virologi-
cal response [26]. Overall, these data indicate a positive 
role of DAA therapy in reducing the incidence rate of HCC 
development after viral eradication. In our study, no dif-
ferences in the occurrence of incident HCC and of decom-
pensating events in short/medium time after viral eradica-
tion in coinfected and monoinfected patients have been 
shown by the survival estimates of these events in both 
groups. Factors as male sex, older age and lower baseline 
albumin concentration, which are surrogate markers of 
advanced liver disease resulted independently associated 
with de novo HCC appearance. Regarding the incidence 
of a decompensating event, this study showed that HIV 
coinfection was not associated with a higher probability of 
developing liver complications in cirrhotic patients, after 
viral eradication. The occurrence rate of a decompensat-
ing event, following viral eradication, was very similar 
in coinfected and monoinfected patients (4.3% vs 4.8%, 
respectively) with no differences in the survival estimates 
in both coinfected and monoinfected populations over the 
short/medium time of follow-up. Older age, male sex and 
low baseline albumin concentration were independently 
associated with decompensation after viral eradication.
Low platelets level was associated to a decompensating 
event at univariate analysis, though it doesn’t result indepen-
dently associated by stepwise regression analysis, most prob-
ably due to not sufficient sample size. In fact, low platelet 
levels have been previously reported as one of the main pre-
dictors of Child–Pugh score deterioration and HCC devel-
opment in the overall PITER cohort [27] and in accordance 
with the results of a previous prospective study, signs of 
portal hypertension can help to stratify the risk of HCC [24].
Regarding the HBV coinfection, the presence of anti-
HBc as marker of previous or ongoing HBV infection is 
significantly higher in coinfected with respect to monoin-
fected patients (45.2% vs 22.4%, respectively). This data 
merits double reflection. First, the presence of HBV infec-
tion markers in almost half of Italian coinfected population 
indicates different epidemiological and baseline clinical pic-
ture between coinfected and monoinfected population and 
second, this data could be taken carefully into consideration 
in the evaluation of clinical outcomes following antiviral 
therapy. Isolated anti-HBc has been of clinical interest over 
the past several years, with growing data that suggested it as 
a serological marker for occult HBV infection with a specific 
role in the HCC development. Similar to recent data, HBV 
infection is significantly associated with newly diagnosed 
HCC in HCV-infected patients with advanced liver disease 
[26]. In our study, it was not possible to evaluate the role of 
HBsAg as predictor markers for HCC development because 
of the small sample size of patients with HBsAg positivity. 
Anti-HBc positivity and other HCV factors associated to 
HCC incidence, as genotype 3, confirm a multistep process 
in HCC development, not only related to HCV viral replica-
tion, once liver cirrhosis is established.
Overall, current data on DAA have shown a lower risk 
of HCC development; however, they were unable to iden-
tify patients at greater risk for HCC occurrence after SVR. 
Surveillance strategy, likely lifelong, is mandatory in these 
patients according to general expert opinion [28].
Although the results of short/medium follow-up time 
following viral eradication have shown no differences in 
the HCC occurrence among coinfected and monoinfected 
patients, longer follow-up data in larger sample size are 
necessary to be evaluated, considering the significant more 
frequent presence of other cofactors of liver disease progres-
sion as presence of HBV coinfection markers and alcohol 
use after viral eradication in patients with HIV coinfection.
These data could be considered representative of HCV 
chronically infected patients with liver cirrhosis in Italy and 
confirm that once a certain severity of liver damage had 
reached during viral replication liver disease could progress 
regardless of viral eradication in coinfected and monoin-
fected patients [8, 29].
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Conclusion
The results of the present study have shown that after success-
ful DAA treatment, patients with advanced liver disease and 
HIV coinfection have a similar probability of developing liver 
complications as HCV monoinfected patients. “Curing” HCV 
is not the ultimate goal in patients with severe liver disease in 
both coinfected and monoinfected patients. Once liver cirrhosis 
is established the risk of disease progression is decreased, but 
still persists regardless of viral eradication. This data has an 
important relevance also on suggesting active HCV surveil-
lance in patients with liver cirrhosis after viral eradication.
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